Biogen
NICE Still Not Recommending Leqembi, Kisunla for Alzheimer's in Updated Draft Guidance
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
In Brief This Week: Eisai, Biogen, Carsgen, VolitionRx, Ocugen, Regenxbio, Guardant Health, Avacta
News items for the week of March 3, 2025.
EC Resumes Review of Eisai, Biogen's Leqembi Application After CHMP Reaffirms Positive Opinion
The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
In Brief This Week: Devyser, Danaher, Beacon Therapeutics, Care Access, IASO Biotherapeutics
News items for the week of Jan. 27, 2025.
Jan 15, 2025
Jul 31, 2024
Jul 29, 2024